Navigation Links
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Date:3/11/2009

, except per share data) 2008 2007 2008 2007 2006 ------------------------------------------------------------------------- ------------------------------------------------------------------------- $ $ $ $ $ Revenues Sales and royalties 4,640 6,435 29,462 28,825 25,123 License fees 2,092 3,705 8,504 12,843 13,652 Other 512 100 512 400 24 ------------------------------------------------------------------------- 7,244 10,240 38,478 42,068 38,799 ------------------------------------------------------------------------- Operating expenses Cost of sales 4,930 3,255 19,278 12,930 11,270 Selling, general and administrative expenses 3,038 5,146 17,325 20,403 16,478 Research and development costs 12,328 13,574 57,448 39,248 27,422 R&D tax credits and grants (137) (1,941) (343) (2,060) (1,564) Depreciation and amortization Property, plant and equipment 316 378 1,515 1,562 2,816 Intangible assets 3,084 757 5,639 4,004 6,148 Impairment of long-lived asset held for sale - 735 - 735 - ------------------------------------------------------------------------- 23,559 21,904 100,862 76,822 62,570 ------------------------------------------------------------------------- Loss from operations (16,315) (11,664) (62,384) (34,754) (23,771) ------------------------------------------------------------------------- Other income (expenses) Interest income 1
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... agreement with Novartis Pharma AG to acquire worldwide rights ... 3 development.  This agreement is conditional on the closing of ... 22, 2014, which are expected to close in the ...
(Date:1/22/2015)... 2015 Shimadzu Scientific Instruments today ... UV-visible spectrophotometer. Offering wavelength scanning from 190 to ... for applications in a variety of industries, including ... user-friendly UV-1280 enables intuitive operation, while the enhanced ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 2015 Protocol Networks brings independent technology ... of brand-neutral, independent consultants, Protocol Networks has recently announced ... over the years, his company has attracted several clients ... Plainfield, as well as others. With the success of ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... the first Wisconsin governor elected to four consecutive terms, and ... governor to be tagged with radio frequency identification for digital ... Thompson, who also served as Secretary of Health and ... of the security technology firm Applied Digital's VeriChip ...
... Madison, Wis. - The Wisconsin Alumni Research Foundation ... Chemicon to commercialize research products using WARF's stem ... Tuesday. , ,Chemicon will have non-exclusive access to WARF's ... patented through the University of Wisconsin-Madison . ...
... Technologies of suburban Madison has received a Phase ... from the National Cancer Institute. The grant is to ... of protein activity, useful for cancer research. , ,Last ... grant for $2.14 million from the National Institute for ...
Cached Biology Technology:Tommy Thompson to get RFID implant 2Tommy Thompson to get RFID implant 3WARF signs stem cell agreement with California firm 2
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in the APAC ... One major trend emerging in this market is advances ... important to upgrade biometric solutions to the latest standard ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
(Date:12/10/2014)... Baptist Medical Center today announced plans for a new medical ... $50 million capital project is part of a larger capital ... The medical education building will be located in the ... 525@vine in Wake Forest Innovation Quarter. Construction will begin immediately ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... of healthcare stakeholders address questions related to health ... disparities in a two-day invitational roundtable on March ... Health Policy, the Agency for Healthcare Research and ... Participants represent the perspectives and concerns of community ...
... Improved environmental conditions have enabled the otter ( Lutra ... years. However, the recovery of populations of this mammal has ... human activities still prevents the species from gaining a foothold. ... acts as a strong impediment to the expansion of the ...
... only a structural support protein in the microenvironment of breast ... However, laminin is far more than just a ... one of the world,s foremost breast cancer scientists have shown ... breast cancer, ,the second most common cancer and second leading ...
Cached Biology News:HIT's impact on health disparities: Will it help or harm? 2Otters on road to recovery in Andalusia 2Berkeley Lab researchers illuminate laminin's role in cancer formation 2Berkeley Lab researchers illuminate laminin's role in cancer formation 3Berkeley Lab researchers illuminate laminin's role in cancer formation 4Berkeley Lab researchers illuminate laminin's role in cancer formation 5
... the 11(R)-LOs of the sea urchin, ... hydra, H. vulgaris. The biological activity ... and tentacle regeneration, respectively, in these ... aspirin-treated recombinant COX-2 is incubated with ...
... (PEBP) does not share significant homology ... PEBP is expressed in the central ... and stomach. One important role ... inhibitory activity against several serine proteases ...
... Power Supply is designed specifically ... extensive programming capabilities including eight ... for you to set to ... intuitive PowerEase interface is faster ...
karyopherin alpha2 (2G7)...
Biology Products: